Press Releases
Calidi is at the forefront of the genetic medicine revolution in cancer and other indications
Read the Latest
Calidi Biotherapeutics Reports First Quarter 2024 Operating and Financial Results
Three upcoming posters, including an update from ongoing Phase 1 trial of Calidi’s CLD-101 program,…
Calidi Biotherapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting
SAN DIEGO–(BUSINESS WIRE)– Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing…
Calidi Biotherapeutics, Inc. Announces Closing of $6.1 Million Public Offering
SAN DIEGO–(BUSINESS WIRE)–Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing…
Calidi Biotherapeutics, Inc. Announces Pricing of $6.1 Million Public Offering
SAN DIEGO–(BUSINESS WIRE)–Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing…
Calidi Biotherapeutics Presents New Data on the Mechanisms of Action for Virotherapy-Loaded Stem Cells Used in the Company’s Novel Immunotherapies at the AACR Annual Meeting 2024
Data supports CLD-101 and CLD-201’s first-in-class use of stem cells to protect and potentiate antitumor…
Calidi Biotherapeutics and City of Hope Announce Funding from the California Institute for Regenerative Medicine (CIRM) to Advance CLD-101 (NeuroNova) in Ovarian Cancer
City of Hope was awarded $5.3 million from CIRM to develop a treatment for metastatic…